|Bid||6.27 x 800|
|Ask||6.45 x 800|
|Day's range||6.20 - 6.45|
|52-week range||5.45 - 23.85|
|Beta (5Y monthly)||1.17|
|PE ratio (TTM)||N/A|
|Earnings date||08 Nov 2021 - 12 Nov 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||35.00|
Omeros (OMER) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Omeros (OMER) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Bad news the company received today from the FDA surprised investors more than it probably should have.